Interface Biologics Enters the Neurology Market with 510(k) Clearance of Arkis BioSciences® CerebroFlo™ EVD Catheter with Endexo® Technology

TORONTO, ONTARIO Sept. 26, 2017 - Interface Biologics, a privately held, commercial stage company developing innovative material science technologies that save lives and improve patient outcomes, is pleased to announce that Arkis BioSciences® has received 510(k) clearance from U.S. Food and Drug Administration (FDA) for its exclusive CerebroFlo™ EVD Catheter with IBI's Endexo® technology.

I am pleased that Arkis has received 510(k) clearance for the EVD Catheter as it represents a beachhead for Endexo technology applications in the brain. With Endexo’s proven effectiveness at reducing DVT and infections, and this recent 510(k) clearance, we are extremely excited about the prospects for Endexo in Neurology and other categories.
— Mark Steedman, V.P. Business Development, Interface Biologics, Inc.

For the full press release click here